Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Free Cash Flow (2016 - 2025)

Collegium Pharmaceutical has reported Free Cash Flow over the past 10 years, most recently at $123.0 million for Q4 2025.

  • Quarterly results put Free Cash Flow at $123.0 million for Q4 2025, up 43.84% from a year ago — trailing twelve months through Dec 2025 was $329.0 million (up 60.65% YoY), and the annual figure for FY2025 was $329.0 million, up 60.65%.
  • Free Cash Flow for Q4 2025 was $123.0 million at Collegium Pharmaceutical, up from $78.2 million in the prior quarter.
  • Over the last five years, Free Cash Flow for COLL hit a ceiling of $123.0 million in Q4 2025 and a floor of -$25.4 million in Q1 2022.
  • Median Free Cash Flow over the past 5 years was $58.0 million (2024), compared with a mean of $51.6 million.
  • Biggest five-year swings in Free Cash Flow: plummeted 226.22% in 2022 and later skyrocketed 946.56% in 2025.
  • Collegium Pharmaceutical's Free Cash Flow stood at $35.7 million in 2021, then skyrocketed by 83.24% to $65.4 million in 2022, then rose by 12.35% to $73.5 million in 2023, then rose by 16.45% to $85.5 million in 2024, then skyrocketed by 43.84% to $123.0 million in 2025.
  • The last three reported values for Free Cash Flow were $123.0 million (Q4 2025), $78.2 million (Q3 2025), and $73.1 million (Q2 2025) per Business Quant data.